Mountain View, CA - November 7, 2014 - El Camino Hospital Foundation received a $1 million gift from Los Altos philanthropists Donna and John Shoemaker for the expansion of El Camino Hospital’s mental health services.
Mountain View, Calif. – October 31, 2014 – El Camino Hospital is the first facility in South Bay area to implant the Nanostim™ leadless pacemaker, the world’s first retrievable, non-surgical pacing technology, as part of the LEADLESS II Clinical Trial. Developed for patients with bradycardia – a heart rate that is too slow – the Nanostim device is designed to be placed directly in a patient’s heart without the visible lump, scar and insulated wires (called leads) required for conventional pacemakers.
-Award to be given at White House Ceremony on November 20-
Mountain View, CA - October 22, 2014 -The Fogarty Institute for Innovation, a 501(c)(3) educational non-profit announced that Dr. Thomas Fogarty, the nationally renowned inventor of the balloon catheter, has been awarded the Presidential National Medal of Technology and Innovation, the country's highest honor for achievement and leadership in advancing the fields of science and technology. Dr. Fogarty will receive his award during a ceremony at the White House on November 20th.
Mountain View, CA - October 6, 2014 -The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) has recognized El Camino Hospital – Mountain View, as one of 44 ACS NSQIP participating hospitals that have achieved meritorious outcomes for surgical patient care. As a participant in ACS NSQIP, El Camino Hospital – Mountain View is required to track the outcomes of inpatient and outpatient surgical procedures and collect data that directs patient safety and the quality of surgical care improvements.
-CoreValve® System Now Available to More U.S. Patients than any Other Transcatheter Aortic Valve-
Mountain View, CA - August 14, 2014 El Camino Hospital became one of the first hospitals in California to adopt a new minimally invasive system to treat patients with narrowed, failing aortic heart valves who are considered to be at high risk to undergo surgery.
The U.S. Food and Drug Administration (FDA) approved the Medtronic CoreValve® System to treat patients with severe aortic stenosis who are at high risk for surgery based on groundbreaking research showing the transcatheter heart valve had superior survival rates at one year when compared to open-heart surgery, the current gold standard for aortic valve replacement. The CoreValve System also demonstrated low rates of procedural complications, including stroke, one of the most concerning complications of valve replacement because it can affect survival and quality of life.